[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Impact Factor 2022: 1.4
Cite Score 2022: 2.1
SJR 2022: 0.347
SNIP 2022: 0.545
Publication Charge
►Publication Fee
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 14, Issue 4 (Autumn 2023) ::
Caspian J Intern Med 2023, 14(4): 694-702 Back to browse issues page
Evaluation of the expression of LC3-II and BECLIN1 genes of autophagy pathway in patients with hematological malignancies
Hossein Ayatollahi , Samaneh Boroumand-Noughabi , Gordon Ferns , Maryam Sheikhi , Payam Siyadat , Mehrdad Rostami , Zahra Khoshnegah *
Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. , zkhoshnegah@gmail.com
Abstract:   (408 Views)
Background: Autophagy is a pathway for the degradation of cytoplasmic components, which plays an essential role in various cellular and physiological processes, including cell renewal and survival, and immune responses. While recent studies have shown that they can play a role in cancer treatment, the precise mechanisms of autophagy in leukemogenesis are not fully understood. We have assessed the expression levels of LC3 and BECLIN1 as two crucial autophagy mediators in patients with leukemia.
Methods: This cross-sectional study was performed on bone marrow or peripheral blood samples of 61 leukemia patients (24 AML, 20 ALL, and 17 CML) and compared to 18 healthy controls. Real-time PCR was used to quantitate gene expression. SPSS statistics 16.0 and Graph Pad Prism 8.4.2 software were applied for statistical analysis.
Results: While BECLIN1 expression was significantly lower in AML, ALL, and CML patients as compared to the control group (p < 0.05), LC3 showed significantly different expression only in the AML patients (P= 0.03). There was no significant correlation between the expression levels of BECLIN1 with LC3 (p> 0.05). Whilst the AML LC3high group had a significantly lower lymphocyte count (P= 0.023), the AML BECLIN1low group had a significantly higher MPV levels (P= 0.044). Furthermore, ALL LC3high group indicated a significantly lower HCT count (P= 0.017).
Conclusion: Significant changes in the expression levels of BECLINI and LC3 in hematologic malignancies may indicate a possible role for autophagy in their pathogenesis. However, further studies are warranted to confirm these findings.

Keywords: Autophagy, Hematological malignancy, LC3, BECLIN1, AML, ALL, CML
Full-Text [PDF 461 kb]   (194 Downloads)    
Type of Study: Original Article | Subject: Hematology
Received: 2022/07/10 | Accepted: 2022/10/29 | Published: 2023/09/28
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ayatollahi H, Boroumand-Noughabi S, Ferns G, sheikhi M, Siyadat P, Rostami M et al . Evaluation of the expression of LC3-II and BECLIN1 genes of autophagy pathway in patients with hematological malignancies. Caspian J Intern Med 2023; 14 (4) :694-702
URL: http://caspjim.com/article-1-3561-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 4 (Autumn 2023) Back to browse issues page
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.06 seconds with 39 queries by YEKTAWEB 4624